Cognitive and ataxic adverse events following entrectinib treatment in NTRK1 fusion gene-positive intrahepatic cholangiocarcinoma: a case report

Kazuya Koyama; Hidetaka Iwamoto; Kenji Takahashi; Tetsuhiro Okada; Hidemasa Kawabata; Yohei Kitano; Hiroki Tanabe; Mikihiro Fujiya; Toshikatsu Okumura; Yusuke Mizukami

doi:10.1007/s12328-024-02076-w

Cognitive and ataxic adverse events following entrectinib treatment in NTRK1 fusion gene-positive intrahepatic cholangiocarcinoma: a case report

Clin J Gastroenterol. 2024 Dec 7. doi: 10.1007/s12328-024-02076-w. Online ahead of print.

Authors

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
² Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, 2-1-1-1, Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan. t-kenji@asahikawa-med.ac.jp.
³ Genetic Oncology Department, Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan. t-kenji@asahikawa-med.ac.jp.
⁴ Genetic Oncology Department, Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan.

PMID: 39644450
DOI: 10.1007/s12328-024-02076-w

Abstract

We report the rare case of severe cognitive disorder and ataxia caused by entrectinib in a patient with NTRK1 fusion gene-positive intrahepatic cholangiocarcinoma. The case was a 56-year-old woman after nine courses of GCS therapy. The patient experienced grade 1 muscle weakness on day 4 and grade 3, cognitive disorder on day 7 after receiving entrectinib, which led to hospitalization. The symptoms were reversible and tended to improve after withdrawal of entrectinib. It is crucial to increase awareness of TRKi-specific adverse events and their proper management.

Keywords: Entrectinib; Intrahepatic cholangiocarcinoma; NTRK fusion; TRKi.

Grants and funding

21K07954/Japan Society for the Promotion of Science